NEW YORK (GenomeWeb News) – Transgenomic yesterday said that it has signed a licensing option agreement with Gene Solutions for a set of validated mutations that can form the basis of a diagnostic test for Parkinson's disease.

Under the agreement, the companies will evaluate the ability of Transgenomic's mitochondrial mutation-detection technology to detect and quantify the presence of the mutations – low-level mitochondrial DNA, or mtDNA, variants that have been shown to be present in Parkinson's disease patients but rarely in age-matched control individuals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.